利用超声定义难治性银屑病关节炎的炎症性与非炎症性表型
该多中心横断面研究纳入517例接受生物制剂或靶向合成改善病情抗风湿药治疗的银屑病关节炎患者,其中53例(10.3%)符合难治性银屑病关节炎标准;30例(57%)为持续性炎症表型,23例(43%)为非炎症性表型,两组在肿胀关节数、指炎、甲银屑病及患者总体评估与医生总体评估差值、压痛点数、附着点炎指数和超声活动度与结构损伤评分上存在差异。
要点
- 517例中53例(10.3%)符合难治性银屑病关节炎标准,其中持续性炎症表型30例(57%)、非炎症性表型23例(43%)。
- 持续性炎症表型肿胀关节数更高(2.5 vs 0.0,p<0.001),指炎(20% vs 0%,p=0.030)和甲银屑病(40% vs 13%,p=0.027)更常见。
- 非炎症性表型患者总体评估与医生总体评估差值更大(4.0 vs 0.0,p<0.001),压痛点数更多(16.0 vs 0.0,p=0.009),附着点炎指数更高(5.0 vs 2.0,p=0.023)。
核心结论
- 基于易于检测的临床特征将难治性银屑病关节炎分为持续性炎症表型和非炎症性表型,可支持对患者进行个体化治疗管理。
研究设计与样本
- 多中心横断面研究,纳入接受生物制剂或靶向合成改善病情抗风湿药治疗的银屑病关节炎患者517例。
- 难治性银屑病关节炎定义为对至少2类生物制剂或靶向合成改善病情抗风湿药应答不足且疾病持续活动(DAPSA>14)。
主要发现
- 517例中53例(10.3%)符合难治性银屑病关节炎标准,其中30例(57%)为持续性炎症表型,23例(43%)为非炎症性表型。
- 持续性炎症表型肿胀关节数2.5(IQR 1.0-7.0)vs 非炎症性表型0.0(IQR 0.0-1.0),p<0.001。
- 持续性炎症表型指炎20% vs 非炎症性表型0%,p=0.030;甲银屑病40% vs 13%,p=0.027。
- 非炎症性表型患者总体评估与医生总体评估差值4.0(IQR 2.5-5.0)vs 持续性炎症表型0.0(IQR 0.0-1.5),p<0.001;压痛点数16.0(IQR 0.0-18.0)vs 0.0(IQR 0.0-8.0),p=0.009;SPARCC附着点炎指数5.0(IQR 2.0-8.0)vs 2.0(IQR 0.0-5.0),p=0.023。
- 肌骨超声显示持续性炎症表型活动度评分3.81±2.0 vs 非炎症性表型0.91±0.5,p<0.001;结构损伤评分4.12±1.0 vs 2.38±2.1,p<0.001,活动度和损伤评分在持续性炎症表型中均更高。
关键数值与推荐
- 难治性银屑病关节炎标准:对至少2类生物制剂或靶向合成改善病情抗风湿药应答不足且DAPSA>14。
- 持续性炎症表型与非炎症性表型的分类基于临床和肌骨超声炎症证据的组合。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the prevalence of difficult-to-treat psoriatic arthritis (D2T-PsA) and classify patients with persistent inflammatory PsA (PIPsA) and non-inflammatory PsA (NIPsA) based on a combination of clinical and musculoskeletal ultrasound (MSUS) evidence of inflammation. METHODS: A multicentre cross-sectional study was conducted on PsA patients treated with biological disease-modifying anti-rheumatic drugs/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). D2T-PsA status was characterised by an inadequate response to ≥2 classes of b/tsDMARDs and the persistence of active disease, defined as a DAPSA >14. RESULTS: Out of 517 PsA patients on b/tsDMARDs, 53 (10.3%) met the criteria for D2T-PsA with 30 (57%) classified as PIPsA and 23 (43%) classified as NIPsA. The PIPsA phenotype had higher swollen joint count (2.5 (IQR 1.0-7.0) vs 0.0 (IQR 0.0-1.0), p<0.001), dactylitis (20% vs 0%, p=0.030) and nail psoriasis (40% vs 13%, p=0.027). Conversely, NIPsA patients had significantly greater ΔPtGA-PhGA (4.0 (IQR 2.5-5.0) vs 0.0 (IQR 0.0-1.5), p<0.001), higher tender points (16.0 (IQR 0.0-18.0) vs 0.0 (IQR 0.0-8.0), p=0.009), a higher SPARCC enthesitis index (5.0 (IQR 2.0-8.0) vs 2.0 (IQR 0.0-5.0), p=0.023). The MSUS showed higher ultrasound activity (3.81±2.0 vs 0.91±0.5, p<0.001) and greater structural damage (4.12±1.0 vs 2.38±2.1, p<0.001), with both activity and damage scores being higher in PIPsA patients. CONCLUSION: The classification into PIPsA and NIPsA based on easily detectable clinical features can support a tailored therapeutic management of patients with D2T-PsA.
引用
- Zabotti A, Cabas N, Di Nicola C, et al. Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis. RMD Open. 2025. PMID: 40813109. doi:10.1136/rmdopen-2025-005785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。